학술논문
Risk Factors for Bleeding Events in Japanese Patients with Advanced Lung Cancer: Data from the Rising-VTE/NEJ037 Study.
Document Type
Article
Author
Source
Subject
*CANCER patient psychology
*JAPANESE people
*RESEARCH
*SCIENTIFIC observation
*VEINS
*MULTIVARIATE analysis
*LUNG tumors
*VENOUS thrombosis
*RISK assessment
*PSYCHOSOCIAL factors
*THROMBOEMBOLISM
*DESCRIPTIVE statistics
*RESEARCH funding
*LONGITUDINAL method
*PROPORTIONAL hazards models
*HEMORRHAGE
*DISEASE risk factors
*DISEASE complications
*EVALUATION
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
Language
ISSN
2072-6694
Abstract
Simple Summary: Cancer increases the risk of venous thrombosis (VTE) and anticoagulant therapy is often used to treat this condition. Therefore, it is essential to identify risk factors for bleeding events in these patients. In our study, we used data from the Rising-VTE/NEJ037 study, which involved Japanese patients with advanced lung cancer, to calculate these risk factors. We found that complications with VTE were the most significant risk factor. This finding underscores the importance of carefully assessing the risks and benefits before starting anticoagulant therapy in patients with cancer. Our research aims to inform safer treatment strategies for patients with advanced lung cancer, which could have meaningful implications for their care and treatment approaches in the research community. Despite the occurrence of various hemorrhagic events during advanced lung cancer treatment, few researchers have reported on their risk factors. Moreover, the development of cancer-related thromboembolism indicates anticoagulant use. However, adverse events such as bleeding should be monitored. In this study, we aimed to identify factors that influence the onset of hemorrhagic events in patients with lung cancer. The Rising-VTE/NEJ037 study was a multicenter, prospective, observational study. A total of 1008 patients with lung cancer who were unsuitable for radical resection or radiation were enrolled and followed up for 2 years. Multivariate analysis using a Cox proportional hazard model was performed to compare the outcomes of the time to the onset of hemorrhagic events for 2 years after registration. Hemorrhagic events occurred in 115 patients (11.4%), with 35 (30.4%) experiencing major bleeding. Significant risk factors included venous thromboembolism (VTE) (hazard ratio [HR]: 4.003, p < 0.001) and an Eastern Cooperative Oncology Group Performance Status score of 1 (HR: 2.476, p < 0.001). Factors that significantly reduced hemorrhagic event risk were female sex (HR: 0.454, p = 0.002) and M1a status (HR: 0.542, p = 0.038). VTE is a risk factor for hemorrhagic events in patients with advanced lung cancer, and risks associated with anticoagulant therapy should be considered. [ABSTRACT FROM AUTHOR]